Alnylam Pharmaceuticals, Inc. · NASDAQ:ALNY
Alnylam Pharmaceuticals — American Society of Nephrology 2017
16 slides from Alnylam Pharmaceuticals's conference presentation, Nov 3, 2017
Slide 1: A Phase 1/2 Trial of Lumasiran (ALN-GO1) for Primary Hyperoxaluria Type 1
Samantha Regulatory Affairs, Alnylam A Phase 1/2 Trial of Lumasiran (ALN-GO1), an Investigational RNAi Therapeutic for Primary Hyperoxaluria Type 1 Yaacov Frishberg1, William van't Hoff2, Sally Hulton3, Patrick Haslett4, David V. Erbe4, Tracy McGregor4, Georges Deschênes5 1Shaare Zedek Medical Cente
Slide 2: Background: Primary Hyperoxaluria Type 1 (PH1)
Background Primary Hyperoxaluria Type 1 (PH1) Rare autosomal recessive disorder of increased endogenous oxalate synthesis due to absence of liver peroxisomal enzyme alanine:glyoxylate aminotransferase (AGT) Phenotype varies from ESRD in infancy to occasional stone formation in adulthood Calcium oxal
Slide 3: Background: Systemic Oxalosis in PH1
Background Systemic Oxalosis in PH1 Retinal oxalosis Abdominal X-ray with Patient with bone deformities nephrocalcinosis bilaterally secondary to pathologic fractures Histology of bone marrow with multiple calcium oxalate Marked hepatosplenomegaly due to crystals extra-medullary erythropoiesis; also
Slide 4: Background: Current Therapeutic Approaches
Background Current Therapeutic Approaches No approved medical therapies Goal: Preservation of kidney function • Decreased oxalate production with Vitamin B6 (effective in minority of patients) • Decreased crystallization with high fluid intake, citrate Patients with ESRD • Increased oxalate removal
Slide 5: Lumasiran (Formerly ALN-GO1)
Lumasiran (Formerly ALN-GO1) Lumasiran is an investigational RNAi therapeutic targeting glycolate oxidase (GO) in development for treatment of Primary Hyperoxaluria Type 1 (PH1) Lumasiran is designed to reduce hepatic levels of GO enzyme (encoded by HAO1), thereby depleting substrate necessary for o
Slide 6: Investigational Therapeutic Approach: RNA Interference
Investigational Therapeutic Approach: RNA Interference Harness natural pathway of gene silencing to regulate protein production Sequence-dependent degradation of target mRNA confers exquisite specificity Conjugation to GalNAc allows subcutaneous administration and efficient delivery to hepatocytes G
Slide 7: Lumasiran Therapeutic Hypothesis: Knockdown of Liver GO Enzyme to Reduce Oxalate
Lumasiran Therapeutic Hypothesis Knockdown of Liver GO Enzyme to Reduce Oxalate PH1 Pathway Healthy Pathway PH1 Pathway + Lumasiran 7 AGT, alanine:glyoxylate aminotransferase; DAO, D-amino acid oxidase; GO, glycolate oxidase; PH1, primary hyperoxaluria type 1
Slide 8: Part A Study Results: Plasma Glycolate Levels in Healthy Volunteers
Lumasiran Phase 1/2 Part A Study Results: Plasma Glycolate Levels in Healthy Volunteers Dose-dependent increase in plasma glycolate levels in healthy volunteers after single dose of lumasiran1 Treatment Group: Placebo (N=8) ALN-GO1 0.3 mg/kg (N=6) ALN-GO1 1.0 mg/kg (N=6) ALN-GO1 3.0 mg/kg (N=6) ALN-
Slide 9: Reported Cases of Known or Suspected GO Inactivity
Reported Cases of Known or Suspected GO Inactivity Lumasiran targets GO, key enzyme in pathway of hepatic oxalate production. Many patients with PH1 already have elevated glycolate levels as part of their disease pathophysiology. No known negative impact of elevated glycolate levels. 8 year old boy1
Slide 10: Study Design & Demographics: Part B (Patients with PH1)
Lumasiran Phase 1/2 Study* Study Design & Demographics: Part B (Patients with PH1) Multiple-Ascending Dose (MAD) │ Randomized 3:1, Single-blind, Placebo-controlled 1.0 mg/kg, q28d x 3 SC, N=4 3.0 mg/kg, q28d x 3 SC, N=4 3.0 mg/kg, q84d x 2 SC, N=4 Dosing Complete • Population: PH1 patients, ages 6-6
Slide 11: Safety: Part B (Patients with PH1)
Lumasiran Phase 1/2 Study Initial Results* Safety: Part B (Patients with PH1) Lumasiran generally well tolerated in patients with PH1 No study discontinuations No drug related Serious Adverse Events (SAEs) • Five total SAEs: Kidney stones, Pyelonephritis, Gastroenteritis with Dehydration • Three SAE
Slide 12: Pharmacodynamics: Part B, Cohort 1 (1 mg/kg q28d x 3)
Lumasiran Phase 1/2 Study Initial Results* Pharmacodynamics: Part B (Patients with PH1) Cohort 1: 1 mg/kg q28d x 3 doses Lumasiran reduced urinary oxalate excretion >50%, relative to baseline • Mean maximum reduction of 66%; maximum reduction of 74% Lumasiran Placebo Delayed initial dosing of lumasi
Slide 13: Pharmacodynamics: Part B, Cohort 2 (3 mg/kg q28d x 3)
Lumasiran Phase 1/2 Study Initial Results* Pharmacodynamics: Part B (Patients with PH1) Cohort 2: 3 mg/kg q28d x 3 doses N=4# 100 90 After first dose of lumasiran or Mean 24h Urine Oxalate Content placebo, mean urinary oxalate Relative to Baseline (%) 80 70 excretion at Day 29 decreased by mean of 4
Slide 14: Significance of Decreasing Urinary Oxalate
Significance of Decreasing Urinary Oxalate Lumasiran lowered UOx below 1.1 mmol/24hr/1.73m2 in all patients with baseline excretion ≥ 1.6 mmol/24hr/1.73m2 Renal survival was examined by quartile of urine oxalate (UOx) excretion (mmol/24hr/1.73m2 ) at diagnosis. Among patients with PH who did not hav
Slide 15: Summary and Next Steps
Lumasiran Phase 1/2 Initial Study Results* Summary and Next Steps Lumasiran (ALN-GO1): subcutaneously administered investigational RNAi therapeutic designed to reduce hepatic production of oxalate in patients with Primary Hyperoxaluria Type 1 (PH1) Multiple doses of lumasiran have been well tolerate
Slide 16: Acknowledgements
Acknowledgements Thank you to the patients, investigators, and study staff who participated in these studies ALN-GO1-001 Investigators Reham Almardini Jérôme Harambat Ulrike Lorch Pierre Cochat Bernd Hoppe Daniella Magen George Deschenes Sally-Anne Hulton Dawn Milliner Yaacov Frishberg John Lieske S
Alnylam Pharmaceuticals — American Society of Nephrology 2017 on 6ix